Photo from wikipedia
Rituximab, which is used in autoimmune rheumatic diseases (ARD), can cause both an increased risk of development of COVID‐19 disease and re‐infection due to its potent and long‐acting immunosuppression. So,… Click to show full abstract
Rituximab, which is used in autoimmune rheumatic diseases (ARD), can cause both an increased risk of development of COVID‐19 disease and re‐infection due to its potent and long‐acting immunosuppression. So, we aimed to evaluate the frequency, risk factors and re‐infection rates of COVID‐19 in ARD patients receiving rituximab.
Keywords:
covid disease;
autoimmune rheumatic;
disease;
frequency risk;
risk factors;
risk
Journal Title: International Journal of Rheumatic Diseases
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: International Journal of Rheumatic Diseases
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!